April 16, 2020 Treating people with lupus earlier with belimumab (Benlysta) may work better than as a last option according to a study just published in the well-respected journal Arthritis & Rheumatology Researchers in Italy analyzed data from 466 people with lupus at 24 centers in Italy who were receiving belimumab intravenously. They looked at […] READ MORE
April 16, 2020 The Lupus Research Alliance is pleased to share news that promises to speed up testing and review of a potential new treatment for lupus. The U.S. Food and Drug Administration granted fast-track designation to RC18, in development by a company in China, RemeGen. The FDA defines fast track as “a process designed […] READ MORE
April 12, 2020 Today, the Lupus Research Alliance (LRA) Scientific Advisory Board Chair Dr. Gary Koretzky emailed top federal health officials a strong letter calling attention to concerns about availability of hydroxychloroquine for patients with systemic lupus erythematosus. The letter was addressed to: Alex M. Azar II, JD, Secretary, Health and Human Services; Stephen […] READ MORE
8 de abril de 2020 Estimado amigo de Lupus Research Alliance: Como sabrá, debido a la posibilidad de que Plaquenil (hidroxicloroquina) sea útil para tratar la COVID-19, se ha generado una importante escasez que dificulta en gran medida que los pacientes con lupus que dependen del medicamento resurtan sus recetas. Si bien esta escasez es más […] READ MORE
New York, NY, April 7, 2020 – Lupus Therapeutics, the clinical trial affiliate of the Lupus Research Alliance (LRA), announced today that it is embarking on a clinical study to assess the potential benefit of hydroxychloroquine and/or other lupus therapies in preventing or reducing the symptoms of COVID-19 in people with lupus. The study […] READ MORE
7 de abril de 2020 Nueva York, NY, 7 de abril de 2020 – Lupus Therapeutics, la filial de ensayos clínicos de Lupus Research Alliance (LRA), anunció hoy que está iniciando un estudio clínico para evaluar el posible beneficio de la hidroxicloroquina u otras terapias para el lupus con el fin de evitar o […] READ MORE
April 3, 2020 The Lupus Research Alliance (LRA) hosted a live webcast April 2, 2020 on COVID-19 for people with lupus that you won’t want to miss – so click here to view the full video recording. The webast addressed the most frequently asked questions doctors are hearing from people with lupus, put the hydroxychloroquine […] READ MORE
April 3, 2020 The President and CEO of the LRA, Kenneth Farber wrote personally to Speaker Nancy Pelosi and Leader Kevin McCarthy in the House of Representatives and Leader Mitch McConnell and Leader Chuck Schumer in the Senate asking that “any COVID-19 response and recovery package include provisions to ensure lupus patients maintain access to […] READ MORE
April 1, 2020 An investigational treatment, iguratimod showed positive results in an early clinical study of people with lupus nephritis that is refractory, meaning it has stubbornly resisted previous treatment with at least two immunosuppressants. Results were reported in Arthritis Research & Therapy. The small study included 14 patients with refractory lupus nephritis. Each were […] READ MORE
April 1, 2020 Thirteen new applications for promising scientific studies were just recommended for funding through the Lupus Research Program (LRP) within the Department of Defense! The $5 million in awards for Fiscal Year 2019 brings the total to $15 million over three years. The dedicated Lupus Research Program was first established in 2017 under […] READ MORE
March 31, 2020 A statement issued March 29 by the U.S. Department of Health and Human Services (HHS) announced that millions of donated doses of hydroxychloroquine sulfate and chloroquine phosphate had been accepted into the Strategic National Stockpile. In addition, the statement announced that the Food and Drug Administration has granted Emergency Use Authorization (EUA) […] READ MORE
March 30, 2020 The rheumatology community has been in discussions with the U.S. Food and Drug Administration and many pharmaceutical companies about the potential shortage of hydroxychloroquine (brand name Plaquenil) in the COVID-19 epidemic, and we are seeing much progress to increase its production and availability. The LRA especially thanks Sandoz, the generics division of […] READ MORE
